ReviewThe Korean journal of internal medicine2017
Reversal of liver cirrhosis: current evidence and expectations.
Review in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 148 citations in OpenAlex.
- Preparation of Oral Artesunate-Chitosan Oligosaccharide-Retinoic Acid Copolymer Micelles for Attenuating Hepatic Fibrosis.Pharmaceutics · 2026Article
- Extracellular Vesicle fromInternational journal of molecular sciences · 2026Article
- EWSR1 as a regulatory target in hepatic stellate cell apoptosis and liver fibrosis therapy.Biochemistry and biophysics reports · 2026Review
- Integrated metabolomics and 16S rRNA sequencing reveal the mechanism of total flavones of Abelmoschus manihot (L.) Medic against liver fibrosis.Scientific reports · 2026Article
- Targeting NF-kappa B/proinflammatory cytokines/ TGF-β/ TIMP-1 pathway by crocin enhances recovery from hepatic fibrosis in rats.Scientific reports · 2026Article
- Identifying liver cirrhosis in patients with chronic hepatitis B: an interpretable machine learning algorithm based on LSM.Annals of medicine · 2025Article
- Recent Advances in Three-Dimensional In Vitro Models for Studies of Liver Fibrosis.Tissue engineering and regenerative medicine · 2025Review
- Correlations of three scoring systems with the prognosis of patients with liver cirrhosis complicated with sepsis syndrome.World journal of gastrointestinal surgery · 2025Article
- Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.Hepatology international · 2025Review
- Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2025Review
- Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis.Frontiers in pharmacology · 2025Review
- Microplastics and nanoplastics: Emerging drivers of liver damage and metabolic dysfunction.Hepatology forum · 2025Review
- Liver cirrhosis in metabolic dysfunction-associated steatohepatitis.Gastroenterology report · 2025Review
- Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".Clinical and molecular hepatology · 2024Article
- Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography.Diagnostics (Basel, Switzerland) · 2024Article
- Multiparametric MRI-based whole-liver radiomics for predicting early-stage liver fibrosis in rabbits.The British journal of radiology · 2024Article
- Splenectomy ameliorates liver cirrhosis by restoring the gut microbiota balance.Cellular and molecular life sciences : CMLS · 2024Article
- A Case Report on Management of Liver Cirrhosis Using Ayurveda and Integrative Approach of Treatment.Case reports in hepatology · 2024Article
- Course of Esophageal Strictures in Eosinophilic Esophagitis Using Structured Esophagram Protocol.Gastro hep advances · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.